Relay Therapeutics CFO Sells $27,000 in Shares

Thomas Catinazzo reduces his stake in the biotech company by 0.83%

Apr. 10, 2026 at 10:18am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of complex financial machinery and equipment, conveying a sense of institutional power and the tangible mechanics of the financial system.An insider stock sale by Relay Therapeutics' CFO raises questions about the company's valuation and management's confidence in its future.Cambridge Today

Relay Therapeutics, Inc. (NASDAQ:RLAY) Chief Financial Officer Thomas Catinazzo sold 1,800 shares of the company's stock on Thursday, April 9th. The shares were sold at an average price of $15.00, for a total value of $27,000. Following the sale, Catinazzo still owns 213,867 shares of Relay Therapeutics, valued at approximately $3.2 million.

Why it matters

Insider trading activity can provide insights into a company's financial health and management's confidence in the business. Catinazzo's sale represents a small reduction in his overall stake, but it may signal that he sees limited upside in Relay Therapeutics' stock in the near term.

The details

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Catinazzo has made several other stock sales in recent months, including 17,717 shares on April 7th and smaller transactions in January.

  • On Thursday, April 9, 2026, Catinazzo sold 1,800 shares.
  • On Tuesday, April 7, 2026, Catinazzo sold 17,717 shares.
  • On Wednesday, January 28, 2026, Catinazzo sold 1,695 shares.
  • On Tuesday, January 27, 2026, Catinazzo sold 13,820 shares.

The players

Thomas Catinazzo

The Chief Financial Officer of Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology.

Got photos? Submit your photos here. ›

What they’re saying

“This represents a 0.83% decrease in their position.”

— Thomas Catinazzo, Chief Financial Officer

What’s next

Investors will likely continue to monitor Relay Therapeutics' insider trading activity for any signs of management's confidence in the company's long-term prospects.

The takeaway

Catinazzo's stock sale, while relatively small, could indicate that he sees limited near-term upside in Relay Therapeutics' share price. However, the company's strong pipeline and institutional investor support suggest it remains a promising biotech play.